Physician profile
Kenneth E Rose
NPI 1215921978
$9,863.94
in general payments reported to CMS, 2019-2025
40 companies · $527 in 2025
The $527 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,258 · 2020: $1,846 · 2021: $1,858 · 2022: $1,347 · 2023: $1,139 · 2024: $889 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,543 · Education: $11.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,542.67 |
| Education | $11.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,198.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,211.42 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $784.35 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $759.97 | 2021-2024 | Vraylar, Ubrelvy, Qulipta |
| Janssen Pharmaceuticals, INC | $592.55 | 2019-2022 | |
| Glaxosmithkline, LLC. | $526.23 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $433.54 | 2019-2024 | |
| Amgen INC. | $353.98 | 2019-2025 | Prolia, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $334.70 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $325.57 | 2019-2024 | |
| Amarin Pharma, INC. | $298.71 | 2019-2022 | |
| Astellas Pharma US INC | $277.37 | 2019-2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $274.04 | 2019-2023 | Trintellix |
| Merck Sharp & Dohme LLC | $209.77 | 2021-2025 | Verquvo, Pifeltro, Belsomra |
| Bayer Healthcare Pharmaceuticals INC. | $174.10 | 2021-2024 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.